Let's get something straight right away. The premise in your questions needs correction. Jubilant Pharmova isn't seeing Drug Discovery margins at 26%—they're at 23.9% in FY25, up from 23.7% the year before. And CRDMO revenue growth isn't muted at 2%—it grew 5% to ₹11,510 crore. Annual Report +3
Similarly, Sai Life Sciences isn't delivering 12% consolidated growth or 13% PAT margins. The real story is more impressive: 29% revenue growth to ₹2,192 crore and PAT margins jumping to 16% from 10%. Annual Report +1
These aren't just accounting differences. They reveal fundamentally different business models at work.
Here's what's actually happening at Jubilant. Drug Discovery Services revenue grew 27% to ₹5,699 crore, with EBITDA climbing 29% to ₹1,364 crore. The margin expansion to 23.9% isn't magic—it's about customer mix. Annual Report
Revenue from large pharma companies increased 5x in the past year, and Jubilant now serves 8 of the top 20 global pharmaceutical companies. Big pharma pays better and sticks around longer. Management wants to triple discovery revenues from the FY24 base of ₹4,485 crore by FY30 and push margins beyond 25%. Annual Report +2
But here's the rub: while discovery services are firing on all cylinders, the broader CRDMO segment is growing at just 5% because the API business is being transitioned to Jubilant Biosys for synergies. It's a strategic pivot, not a growth problem. Investor Presentation
Sai Life Sciences is playing a different game. Their CRO business grew 28% in H1FY26 to ₹367 crore, and has delivered 35% CAGR from FY21 to FY25. But the real secret sauce is in how they sell. Investor Presentation +1
More than 65% of revenues come from customers who use multiple discovery services. Over 65% of discovery programs are integrated, combining next-gen biology, automation, and AI. This isn't just cross-selling—it's building sticky relationships where customers can't easily leave. Investor Presentation +2
The integrated model shows up in the numbers. Sai operates as a full-service CRDMO with CDMO contributing 64-66% of revenue and CRO making up 34-36%. They've got 30 commercial molecules, 40+ programs in clinical stages, and 5 molecules that have gone from discovery to market. That's the power of end-to-end execution. Investor Presentation +2
This is where the paths really diverge. Jubilant is betting big with borrowed money. Net debt-to-EBITDA has risen from 1.1x in March 2025 to 1.5x by September 2025. The company is investing US$150 million to expand Drug Discovery Services from 1,000 FTEs to 4,000 FTEs by FY30. Add US$50 million for PET radiopharmacy expansion and US$285 million for CDMO sterile injectables, and you're looking at nearly US$485 million in total investments. Investor Presentation +4
Jubilant's net debt stands at ₹1,897 crore as of Q2 FY26—not the ₹2,338 crore mentioned in your query. Interest coverage is 5.1x, adequate but not comfortable for this level of expansion. Management targets zero net debt by FY30 and ROCE in the high teens, but that requires flawless execution. Investor Presentation +3
Sai Life Sciences couldn't be more different. Net debt-to-EBITDA is 0.04x—essentially debt-neutral. Interest coverage runs between 13.36x and 16.76x. This pristine balance sheet gives them enormous flexibility. Investor Presentation +1
Sai's FY27 capex program of ₹1,100-1,300 crore is nearly double the ₹633 crore spent in FY26. The allocation is telling: 75% toward capacity expansion, 25% toward capabilities and AI. This isn't random—they're running at 65% capacity utilization in Q1 FY27, which means they've got clear visibility on demand absorption. Investor Presentation +3
The return profile makes sense.
With 18 of the 25 largest pharmaceutical companies as customers and 40+ programs advancing through clinical stages, Sai's pipeline visibility is exceptional. Investor Presentation
The profit stories tell you everything. Jubilant's net profit has swung wildly: ₹413 crore in FY22, a loss of ₹65 crore in FY23, then back to ₹398 crore in FY26. This volatility reflects a diversified but complex business structure with moving parts across radiopharma, generics, and CRDMO. Annual Report
Sai's profit trajectory is a straight line upward: from ₹6 crore in FY22 to ₹349 crore in FY26. The stock has responded, climbing 70% in 2026 and trading at premium valuations. The market rewards predictability, especially when it comes with 18.2% ROCE and consistent margin expansion. Annual Report +1
Both companies face structural headwinds. China controls 18-21% of the global CRDMO market compared to India's 2-3%. That's a massive competitive disadvantage on pricing and capacity. Chinese players can scale faster and price more aggressively. Annual Report
Then there's the AI disruption. Virtual screening and molecular design are threatening traditional laboratory-based discovery models. Both companies are responding—Sai with >65% of discovery programs already integrated with AI and automation, Jubilant with investments in discovery informatics and molecular modelling. But this is an arms race that never ends. Investor Presentation +1
Sai Life Sciences is expanding into ADCs, peptides, and oligonucleotides—the fastest-growing segments in CRDMO. This focused specialization builds deeper expertise and stronger customer relationships in high-value niches. Investor Presentation
Jubilant is diversifying across radiopharma, generics, and discovery services. It's broader but less focused. The PET radiopharmacy expansion from 3 to 9 facilities and the US$285 million CDMO sterile injectables investment create multiple growth vectors, but also more complexity. Investor Presentation +1
Sai Life Sciences is executing the pure-play integrated CRDMO model with superior financial discipline. The 65% cross-service utilization, debt-neutral balance sheet, and 18.2% ROCE create a self-reinforcing competitive advantage. The premium valuation is justified. Investor Presentation +2
Jubilant Pharmova is taking a calculated risk. The US$485 million expansion program could transform the company if executed flawlessly, but the elevated leverage and earnings volatility increase the risk profile. The 41x PE ratio assumes everything goes right—Montreal facility remediation, SPECT radiopharmaceutical normalization, and discovery services hitting the 25% margin target. Annual Report
Both companies are chasing the same opportunity in India's growing CRDMO market. But Sai's focused execution and financial flexibility give it the edge in converting that opportunity into sustainable value creation.
